Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recursion Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RXRX
)
4.835
+0.125 (+2.65%)
Streaming Delayed Price
Updated: 1:45 PM EST, Dec 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
↗
March 30, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
↗
March 10, 2025
Fiserv recently completed its acquisition of Payfare Inc. On "Mad Money Lightning Round," Jim Cramer called it "one of the greatest fintechs."
Via
Benzinga
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
↗
March 08, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
↗
March 08, 2025
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.
Via
Benzinga
Where Recursion Pharmaceuticals Stands With Analysts
↗
February 06, 2025
Via
Benzinga
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
March 18, 2025
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Why Recursion Pharmaceuticals Stock Is Sinking Today
↗
March 10, 2025
Via
The Motley Fool
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
↗
March 07, 2025
Via
The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
↗
March 07, 2025
The term "game-changing" is overused for too many up-and-coming companies, but in this case, the description fits.
Via
The Motley Fool
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
↗
March 06, 2025
Via
The Motley Fool
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
↗
March 03, 2025
Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.
Via
Benzinga
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
↗
March 02, 2025
Leerink cited concerns over high cash burn and execution risks in deal-making and clinical development over the next year.
Via
Stocktwits
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
↗
March 01, 2025
Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Via
Benzinga
Topics
Artificial Intelligence
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
February 28, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Earnings Scheduled For February 28, 2025
↗
February 28, 2025
Via
Benzinga
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
February 24, 2025
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
February 21, 2025
Recursion Pharmaceuticals' stock has soared due to Nvidia's continued investment, positioning the company as a leader in AI-driven drug discovery.
Via
MarketBeat
Topics
Artificial Intelligence
Regulatory Compliance
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst
↗
February 20, 2025
Nvidia sold their stake in some high-flying stocks recently.
Via
The Motley Fool
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
↗
February 18, 2025
Via
Benzinga
25 Top AI Stocks That Could Boost Your Portfolio
↗
February 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
February 19, 2025
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge
↗
February 18, 2025
The Japanese conglomerate’s bet comes amid growing AI sector momentum, fueled in part by chipmaking giant Nvidia, which also holds over 7.7 million Recursion shares.
Via
Stocktwits
Topics
Artificial Intelligence
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
↗
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
Altitude Lab Startups Raise $154M in Capital
February 18, 2025
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones
From
Recursion Pharmaceuticals
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 14, 2025
Via
Benzinga
Why Recursion Pharmaceuticals Stock Is Soaring Today
↗
February 14, 2025
Via
The Motley Fool
Nvidia Invests in These 2 Artificial Intelligence (AI) Stocks and Sells These 3 Others
↗
February 14, 2025
Nvidia's 13F revealed some interesting choices.
Via
The Motley Fool
Topics
Artificial Intelligence
Why SoundHound AI and Serve Robotics Stock Crashed on Friday
↗
February 14, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Nvidia Dumps SoundHound, Trims Arm Stake, Buys These 2 Stocks
↗
February 14, 2025
Nvidia disclosed in a regulatory filing Friday that it sold off three tech stocks and added stakes in two others. Nvidia stock rose.
Via
Investor's Business Daily
Biotechs on the Brink: 2 Stocks With Huge Potential
February 14, 2025
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
